This is a correction document to a study published in the journal Lancet. The study, "TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomized, placebo-controlled phase 2 study with BI 764198," was published in 2026, issue 407, pages 587-98. The authors are Trachtman H, Kretzler M, Gesualdo L and colleagues. The error relates to part E of Figure 2, where the doses for patients 5, 6 and 7 should have been given as 20 mg, 20 mg and 80 mg. A correction was made to the online version of the article on February 26, 2026. The document does not contain additional details about the study results or statistics.